346 related articles for article (PubMed ID: 18662879)
41. N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1).
Jetter MC; McNally JJ; Youngman MA; McDonnell ME; Dubin AE; Nasser N; Zhang SP; Codd EE; Colburn RW; Stone DR; Brandt MR; Flores CM; Dax SL
Bioorg Med Chem Lett; 2008 Apr; 18(8):2730-4. PubMed ID: 18359227
[TBL] [Abstract][Full Text] [Related]
42. Potent and orally efficacious benzothiazole amides as TRPV1 antagonists.
Besidski Y; Brown W; Bylund J; Dabrowski M; Dautrey S; Harter M; Horoszok L; Hu Y; Johnson D; Johnstone S; Jones P; Leclerc S; Kolmodin K; Kers I; Labarre M; Labrecque D; Laird J; Lundström T; Martino J; Maudet M; Munro A; Nylöf M; Penwell A; Rotticci D; Slaitas A; Sundgren-Andersson A; Svensson M; Terp G; Villanueva H; Walpole C; Zemribo R; Griffin AM
Bioorg Med Chem Lett; 2012 Oct; 22(19):6205-11. PubMed ID: 22939234
[TBL] [Abstract][Full Text] [Related]
43. TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1.
Conway SJ
Chem Soc Rev; 2008 Aug; 37(8):1530-45. PubMed ID: 18648679
[TBL] [Abstract][Full Text] [Related]
44. In vitro photo-release of a TRPV1 agonist.
Carr JL; Wease KN; Van Ryssen MP; Paterson S; Agate B; Gallagher KA; Brown CT; Scott RH; Conway SJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):208-12. PubMed ID: 16213723
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
[TBL] [Abstract][Full Text] [Related]
46. Synthesis of benzamide derivatives as TRPV1 antagonists.
Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
[TBL] [Abstract][Full Text] [Related]
47. Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity.
Kirrane TM; Boyer SJ; Burke J; Guo X; Snow RJ; Soleymanzadeh L; Swinamer A; Zhang Y; Madwed JB; Kashem M; Kugler S; O'Neill MM
Bioorg Med Chem Lett; 2012 Jan; 22(1):738-42. PubMed ID: 22056746
[TBL] [Abstract][Full Text] [Related]
48. 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists.
Shao B; Huang J; Sun Q; Valenzano KJ; Schmid L; Nolan S
Bioorg Med Chem Lett; 2005 Feb; 15(3):719-23. PubMed ID: 15664844
[TBL] [Abstract][Full Text] [Related]
49. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
[TBL] [Abstract][Full Text] [Related]
50. 4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands.
Kim C; Ann J; Lee S; Kim E; Choi S; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
Bioorg Med Chem; 2018 Aug; 26(15):4509-4517. PubMed ID: 30078610
[TBL] [Abstract][Full Text] [Related]
51. Identification of potent, soluble, and orally active TRPV1 antagonists.
Ratcliffe P; Maclean J; Abernethy L; Clarkson T; Dempster M; Easson AM; Edwards D; Everett K; Feilden H; Littlewood P; McArthur D; McGregor D; McLuskey H; Nimz O; Nisbet LA; Palin R; Tracey H; Walker G
Bioorg Med Chem Lett; 2011 Apr; 21(8):2559-63. PubMed ID: 21435873
[TBL] [Abstract][Full Text] [Related]
52. Discovery of indane propanamides as potent and selective TRPV1 antagonists.
Ahn S; Kim YS; Kim MS; Ann J; Ha H; Yoo YD; Kim YH; Blumberg PM; Frank-Foltyn R; Bahrenberg G; Stockhausen H; Christoph T; Lee J
Bioorg Med Chem Lett; 2020 Feb; 30(3):126838. PubMed ID: 31864799
[TBL] [Abstract][Full Text] [Related]
53. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
[TBL] [Abstract][Full Text] [Related]
54. Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.
Lebsack AD; Branstetter BJ; Hack MD; Xiao W; Peterson ML; Nasser N; Maher MP; Ao H; Bhattacharya A; Kansagara M; Scott BP; Luo L; Rynberg R; Rizzolio M; Chaplan SR; Wickenden AD; Guy Breitenbucher J
Bioorg Med Chem Lett; 2009 Jan; 19(1):40-6. PubMed ID: 19038548
[TBL] [Abstract][Full Text] [Related]
55. Synthesis of Analogues of BCTC Incorporating a Pyrrolidinyl Linker and Biological Evaluation as Transient Receptor Potential Vanilloid 1 Antagonists.
Yan L; Wang J; Pan M; Qiu Q; Huang W; Qian H
Chem Biol Drug Des; 2016 Feb; 87(2):306-11. PubMed ID: 26360809
[TBL] [Abstract][Full Text] [Related]
56. Triazine-based vanilloid 1 receptor open channel blockers: design, synthesis, evaluation, and SAR analysis.
Vidal-Mosquera M; Fernández-Carvajal A; Moure A; Valente P; Planells-Cases R; González-Ros JM; Bujons J; Ferrer-Montiel A; Messeguer A
J Med Chem; 2011 Nov; 54(21):7441-52. PubMed ID: 21950613
[TBL] [Abstract][Full Text] [Related]
57. Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators.
Morera E; De Petrocellis L; Morera L; Moriello AS; Nalli M; Di Marzo V; Ortar G
Bioorg Med Chem Lett; 2012 Feb; 22(4):1674-7. PubMed ID: 22257892
[TBL] [Abstract][Full Text] [Related]
58. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.
Ueda S; Kato M; Inuki S; Ohno H; Evans B; Wang ZX; Peiper SC; Izumi K; Kodama E; Matsuoka M; Nagasawa H; Oishi S; Fujii N
Bioorg Med Chem Lett; 2008 Jul; 18(14):4124-9. PubMed ID: 18539453
[TBL] [Abstract][Full Text] [Related]
59. Synthesis of oxazolo[4,5-c]quinoline TRPV1 antagonists.
Voight EA; Daanen JF; Kort ME
J Org Chem; 2010 Dec; 75(24):8713-5. PubMed ID: 21090730
[TBL] [Abstract][Full Text] [Related]
60. Discovery of a piperidine-4-carboxamide CCR5 antagonist (TAK-220) with highly potent Anti-HIV-1 activity.
Imamura S; Ichikawa T; Nishikawa Y; Kanzaki N; Takashima K; Niwa S; Iizawa Y; Baba M; Sugihara Y
J Med Chem; 2006 May; 49(9):2784-93. PubMed ID: 16640339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
